FIMICS: A panel of long noncoding RNAs for cardiovascular conditions

Huseyin Firat; Lu Zhang; Shounak Baksi; Przemyslaw Leszek; Eric Schordan; Samir Ounzain; Jan Kottwitz; Dimitri Patriki; Bettina Heidecker; Thomas F Lüscher; Thierry Pedrazzini; Yvan Devaux; EU-CardioRNA COST Action (CA17129)

doi:10.1016/j.heliyon.2023.e13087

FIMICS: A panel of long noncoding RNAs for cardiovascular conditions

Heliyon. 2023 Jan 20;9(1):e13087. doi: 10.1016/j.heliyon.2023.e13087. eCollection 2023 Jan.

Affiliations

¹ Firalis SA, Huningue, France.
² Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg.
³ The Heart Failure and Transplantology Department, Institute of Cardiology, Warsaw, Poland.
⁴ HAYA Therapeutics, Lausanne, Vaud, Switzerland.
⁵ Division of Anesthesiology, Intensive Care, Rescue and Pain Medicine, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
⁶ Department of Cardiology, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
⁷ Charité Universitätsmedizin Berlin, Germany.
⁸ Royal Brompton & Harefield Hospitals GSTT, Imperial College and Kings College London, U.K. and Center for Molecular Cardiology, University of Zurich, Switzerland.
⁹ Experimental Cardiology Unit, Department of Cardiovascular Medicine, University of Lausanne Medical School, Lausanne, Switzerland.

Abstract

Cardiovascular disorders such as heart failure are leading causes of mortality. Patient stratification via identification of novel biomarkers could improve management of cardiovascular diseases of complex etiologies. Long-noncoding RNAs (lncRNAs) are highly tissue-specific in nature and have emerged as important biomarkers in human diseases. In this study, we aimed to identify cardiac-enriched lncRNAs as potential biomarkers for cardiovascular conditions. Deep RNA sequencing and quantitative PCR identified differentially expressed lncRNAs between failing and non-failing hearts. An independent dataset was used to evaluate the enrichment of lncRNAs in normal hearts. We identified a panel of 2906 lncRNAs, named FIMICS, that were either cardiac-enriched or differentially expressed between failing and non-failing hearts. Expression of lncRNAs in blood samples differentiated patients with myocarditis and acute myocardial infarction. We hereby present the FIMICS panel, a readily available tool to provide insights into cardiovascular pathologies and which could be helpful for diagnosis, monitoring and prognosis purposes.

Keywords: Biomarker; Cardiac enriched RNA; Cardiovascular condition; Deep RNA sequencing; Heart failure; Long-noncoding RNA.